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Teenage pregnancy is considered a key indicator of 
adolescent health for good reason.1 The associations 
between teenage births and mortality, morbidity, and 
social and economic hardship for the mother and child 
are well established. Research over many decades has 
provided us with a good understanding of the underlying 
factors for the complex issue of teenage pregnancy and 
reasonable evidence for what strategies work to limit it. 
In The Lancet, Kaye Wellings and colleagues2 present the 
impact of the UK Teenage Pregnancy Strategy on rates 
of teenage abortions and births in England over the 
13 years after its introduction in 2000.3
The Teenage Pregnancy Strategy was a complex, 
intersectoral, and multicomponent intervention, 
informed by available evidence on likely eﬀ ective 
strategies to reduce pregnancies, from inception 
throughout its funding period. There were three main 
components of the strategy. The ﬁ rst element was a 
whole-government approach to administration, headed 
by a cross-departmental ministerial task force (spanning 
the departments of health, education, and employment), 
monitored by an independent national advisory group 
and implemented by funded regional and local service 
coordinators and partnership boards. The second element 
was improved prevention eﬀ orts, including: high quality 
education about sex and relationships in schools; better 
access to eﬀ ective contraception; enhanced eﬀ orts 
targeting the most at-risk groups, and young males; a 
media campaign with separate components for young 
people and parents; and a print and broadcast media 
campaign. The third element was better support for 
pregnant teenagers and teenage parents to ensure 
completion of education and access to secure housing 
with in-home support for mothers and their children. 
At the mid-course review in 2005, the UK’s national 
conception rate had dropped 11% for those younger than 
18 years and 15% for those younger than 16 years, but 
with variability, including reductions as substantial as 43% 
in one local authority.4 From this point, a more intensive 
approach to lower-performing authorities was adopted.5
In the study by Wellings and colleagues,2 investigators 
combined routinely collected area-level data 
on abortions and births, deprivation, and Local 
Implementation Grant expenditures with individual-
level risk factor information from the three waves of 
the National Surveys of Sexual Attitudes and Lifestyle 
(Natsal) to describe changes in conception, abortions, 
and maternities in individuals younger than 18 years 
in England from 2000 to 2013. The maternity rate 
of individuals younger than 18 years in England has 
decreased slowly but steadily from its peak in 1996–98, 
but much more rapidly from 2007 to 2013, along with 
a decline in the abortion rate, halving the conception 
rate overall. The most substantial reductions were in 
the most deprived areas, where rates were originally 
highest. Participation in work, education, or training by 
young women who became mothers before age 18 years 
doubled over the period of the Teenage Pregnancy 
Strategy. The authors also estimated an absolute 
decrease in conception rate of between 8·2 conceptions 
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(95% CI 5·8–10·5; p<0·0001) and 11·5 conceptions 
(9·5–13·5; p<0·0001) per 1000 women aged 15–17 years 
per £100 Teenage Pregnancy Strategy spend per head. 
This translates to between about £8700 and £12 200 per 
conception prevention, which might seem expensive, 
but is less than a quarter the cost of child support for 
a teenage mother and her child, who are at high risk 
of lifelong intergenerational welfare dependence. As 
reported in the mid-course review,6 the net estimated 
welfare payment per teenage birth, over the 16 years for 
which the family would be eligible for child-contingent 
beneﬁ ts, was £44 566 in 2005 (£61 947 in 2016).
The authors present a convincing case that much of 
the reduction in teenage conception can be attributed 
to the Teenage Pregnancy Strategy. This is the ﬁ rst 
time we have seen a teenage pregnancy prevention 
programme reduce objectively measured teenage 
conceptions, and improve outcomes for teenage 
mothers over a sustained period of time at the national 
level. The programme had many components, and in 
the absence of a careful process assessment, we still 
don’t know which were more eﬀ ective than others, 
however the combination of sex and relationships 
education, increased access to contraception, and social 
inclusion strategies are likely to be necessary elements. 
Other multistrategy programmes (combining education 
and increased access to contraception) have also shown 
success in reducing self-reported pregnancies in study 
samples, mainly in the USA.7
The Teenage Pregnancy Strategy needed a full decade 
of implementation to show its capacity to eﬀ ect change 
on this complex issue. At the mid-course review, rather 
than withdrawing funding in response to a modest 11% 
reduction in conceptions, the task force accelerated 
eﬀ orts. However, as happens often, a change in 
government in 2010 coincided with discontinuation of 
funding of the UK Teenage Pregnancy Strategy. In 2011, 
an investigation by The Guardian8 reported that over a 
third of teenage pregnancy coordinator positions had 
been eliminated, and a parliamentary inquiry yielded no 
further information about disposition of coordination 
positions nationally.9
The UK Teenage Pregnancy Strategy is an impressive 
example of how a sustained, multilevel, and 
multicomponent intervention, such as that advocated 
by the recent Lancet Commission on adolescent health,10 
can impact a complex health and social issue, with high 
cost-eﬀ ectiveness. By way of comparison, the UK human 
papillomavirus (HPV) vaccination programme is another 
example of a complex health intervention programme, 
which has achieved similarly impressive success.11–13 
Would the UK Government seriously consider defunding 
and devolving all responsibility for HPV vaccination 
programme implementation to local authorities and 
their budgets? Ongoing monitoring and support should 
be provided to local authorities to ensure that the 
key elements of the Teenage Pregnancy Strategy and 
low rates of teenage pregnancy remain a core goal for 
the UK. Teenage pregnancy is no longer a problem too 
hard to be solved: a country’s teenage pregnancy rates 
can be lowered and, further, the association between 
intergenerational poverty and teenage pregnancy can 
be attenuated, long term.
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Few issues provoke as much disagreement, even anger, as 
the question of the private sector’s role in delivering health 
care. Supporting a contribution by the private health sector 
towards achieving the goal of universal health coverage is 
seen as a betrayal of public welfare by many critics. For those 
of us brought up with (or trained within) a publicly ﬁ nanced 
health system (such as the UK’s National Health Service), 
private provision of health care may be anathema. Very 
often, we will rail against private providers—the proﬁ t they 
make from the sick, the catastrophic health expenditures 
they may cause, or the latitude they enjoy to exploit the poor 
in systems where government regulation is weak or non-
existent. But, as Kara Hanson, Barbara McPake, and their 
colleagues set out in this Lancet Series on the private sector 
in health, these simplistic views may hinder rather than help 
our understanding about what the private sector is and how 
it can best contribute to broad health goals.1–4
The private sector in health care is not going away. 
Indeed, it has a large and expanding part to play in the 
health systems of all low-income and middle-income 
nations. Provision of private health care varies greatly 
between and within countries, as does the quality of 
that care. Private health care ranges from the most basic 
care oﬀ ered by travelling merchants selling medicines to 
highly commercialised hospital care. The task of those 
concerned with health should be to subject the private 
sector to scrutiny—description, analysis, and evaluation. 
What this Series makes abundantly and disappointingly 
clear is that the evidence on which to make wise policy 
decisions concerning the private sector is often weak or 
absent. That situation must change. 
Maureen Mackintosh and colleagues1 argue that a 
good-quality and accessible public sector system will 
lead to a private health system with similarly desirable 
characteristics. Research so far has usually compared 
provision of care by the private sector with that of the 
public sector, which might be misleading, according to 
Rosemary Morgan and colleagues.2 Our collective goal 
should not be to arrive at some settled ideological position 
either for or against the private sector. Instead, we should 
keep the objective of universal health coverage ﬁ rmly in 
mind, ensuring that whatever mix of public and private 
health provision exists in a particular setting meets that 
goal. What we do know is that the public and private 
sectors cannot be seen as mutually exclusive entities 
within a health system. Each depends upon the other, 
and the performance of one is often intimately linked to 
the performance of the other. Public and private sectors 
therefore should be viewed as entwined elements of a 
whole health system, and managed as such. 
So far, ways to improve provision of health care by the 
private sector have been limited to banning, regulation, 
subsidy, and purchase of services, as outlined by Dominic 
Montagu and colleagues.3 Banning or heavily regulating 
the private sector are certainly policy options. But neither 
may be feasible nor fully practical in countries with 
weak governments or weak governmental institutions. 
Moreover, there is no ideal prescription for the perfect mix 
of public and private health-care provision. Every country is 
diﬀ erent, and each country’s government will have to make 
choices to manage its public and private sectors with the 
overall objective of universal health coverage in mind. 
The perils and possibilities of the private health sector
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